Resumen:
Pharmaceutical polymorphism may have great consequences in the life of an active pharmaceutical
ingredient (API), affecting important physicochemical and biopharmaceutical properties such as the
stability, dissolution (DR) and absorption rates. These differences are usually more evident when
amorphous and crystalline phases of an API are compared, because amorphous solids are far from the
equilibrium, showing higher solubility and DR than their crystalline counterparts, and being more
unstable with high tendencies to devitrify. In this work, we evaluate the solid-state stability and intrinsic
dissolution behavior of two solid-state forms of AZT-Ac, a zidovudine (AZT) derivative which shows
comparable antiviral activity and less cytotoxicity than AZT. AZT-Ac-1 is a crystalline form and AZT-Ac
tbw is an amorphous phase obtained by lyophillisation from t-butanol-water.